Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 3 4Phase 4 2Phase 1 1

Status

Completed 37Terminated 13Withdrawn 4Unknown 3Recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 25Neoplasms 19Prostatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 8Ovarian Neoplasms 8Head and Neck Neoplasms 8Pain 7Lung Neoplasms 7Leukemia, Myeloid, Acute 7Squamous Cell Carcinoma of Head and Neck 6Neoplasm Metastasis 6Lymphoma, Follicular 6Leukemia 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Non-Muscle Invasive Bladder Neoplasms 5Brain Neoplasms 5Small Cell Lung Carcinoma 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leiomyoma 4Carcinoma 4Urologic Neoplasms 3Urogenital Neoplasms 3Papillomavirus Infections 3

Interventions

vilaprisan 1ulipristal acetate 1telapristone acetate 1Leuprolide 1Iron 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Leiomyoma × Clear all
NCT03699176 2020-01-18

ASTEROID 7

Bayer

Phase 3 Withdrawn

Leiomyoma

NCT02736435 2018-02-06

Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound

Thunder Bay Regional Health Research Institute

Phase 3 Withdrawn

Leiomyoma, Myofibroma

NCT00874302 2014-06-27

Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms

Repros Therapeutics Inc.

Phase 3 Withdrawn

Leiomyoma

NCT01553123 2013-02-07

Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma

Watson Pharmaceuticals

Phase 3 Withdrawn

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡